San Diego, CA -- (SBWIRE) -- 03/18/2021 -- The Shareholders Foundation announced that a deadline is coming up on March 29, 2021 in the lawsuit filed for certain investors of AstraZeneca PLC (NASDAQ: AZN).

Investors who purchased shares of AstraZeneca PLC (NASDAQ: AZN) have certain options and there are strict and short deadlines running. Deadline: March 29, 2021. NASDAQ: AZN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The plaintiff alleges on behalf of purchasers of AstraZeneca PLC (NASDAQ: AZN) common shares between May 21, 2020 and November 20, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 21, 2020 and November 20, 2020, the defendants misrepresented facts regarding the Company's ongoing AZD1222 clinical trials and concealed problems that had arisen in the trials, including a dosing error which had been discovered early on by the Company but not disclosed to investors.

Those who purchased shares of AstraZeneca PLC (NASDAQ: AZN) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.